Clinical Trial Update: Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating romosozumab to improve bone mineral density and bone architecture in adults with chronic spinal cord injury and sublesion…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Spinal Cord Injury

Drugs mentioned

• Evenity (romosozumab)

Snippet

Sponsor: VA Office of Research and Development | Conditions: Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI | Phase 2 | Status: ACTIVE_NOT_RECRUITING